CAPS NASDAQ
Capstone Holding Corp.
1W: -10.8%
1M: -25.4%
3M: -44.1%
YTD: -56.8%
1Y: -87.5%
3Y: -98.3%
5Y: -96.2%
$0.39
+0.08 (+27.32%)
Weekly Expected Move ±11.9%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.6M
52W Range0.26-2.14
Volume341,962
Avg Volume2,056,532
Beta-1.52
Dividend—
Analyst Ratings
Company Info
CEOMatthew E. Lipman
Employees36
SectorBasic Materials
IndustryConstruction Materials
IPO Date1993-01-28
Websitecapstoneholdingcorp.com
1275 West Washington Street
Alsip, IL 60803
US
Alsip, IL 60803
US
602-286-5520
About Capstone Holding Corp.
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
Latest News
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| SCHULTZ EDWARD CHRIS | A-Award | 190,000 | — | 2026-03-30 |
| Lipman Matthew E. | A-Award | 356,250 | — | 2026-03-30 |
| TOPOREK MICHAEL | A-Award | 356,250 | — | 2026-03-30 |
| SCHULTZ EDWARD CHRIS | 0 | — | 2025-02-14 | |
| Lipman Matthew E. | 0 | — | 2025-02-14 |